Metabolics

Sermorelin

CAS 86168-78-7
$98 - $797

Sermorelin functions as a synthetic analog of human growth hormone-releasing hormone (GHRH).

Sermorelin

10mg per vial

CAS 86168-78-7

Available packs
2 vials
20mg
5 vials
50mg
10 vials
100mg
20 vials
200mg
In stock
Choose pack
Choose pack
Pack price
Selected pack
20mg pack
2 vials x 10mg · 20mg total · $4.90/mg
Pack price
$98
Quantity
1
$302 to free shipping.
Published certificate history is available below.

Research Use Only. Not for use in diagnostic tests.

Before ordering
  • Independent certificate details, manufacturer IDs, and batch IDs should be reviewed before purchase when available.
  • Order cancellations for full refunds are available before shipment; shipped orders cannot be cancelled or refunded.
  • For damaged or incorrect goods, photograph the outer packaging, inner packaging, and product labels, then email support within 48 hours of carrier delivery.

Swipe horizontally or use the left and right arrow keys to see all product details.

Scroll tables horizontally to view all columns.

Sermorelin

Swipe right to view full table →

Save over 70%!

Product Format
10mg vials
Vial Size
10mg
Vial Capacity
3 mL
Box Combinations
20mg, 50mg, 100mg, 200mg
Cost per milligram
$3.98 – $4.90
Multi-vial Purity
99.94%
Endotoxin Screening
PASSED
Heavy Metals Screening
PASSED
Purity Screening
PASSED
Independently Tested
YES
  • Peptide Partners Manufacturer ID: VI32
  • Batch ID: SER202601
 

Research Studies

(for research purposes only)
 

Study 1: A potentially effective drug for patients with recurrent glioma: sermorelin

Authors: Chang Y, Huang R, Zhai Y, Huang L, Feng Y, Wang D, Chai R, Zhang W, Hu H.

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC8033379/



Scientific Findings

The study investigated the effect of sermorelin on glioma cell lines U87 and LN229. The results showed that sermorelin inhibited the proliferation of these cells in a dose-dependent manner. The study suggests that sermorelin may inhibit tumor cell proliferation by blocking the cell cycle. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analyses found that the Drug Resistance Score (DRS) of sermorelin was negatively correlated with cell proliferation and immune function.



Plain English Interpretation

This research explored whether the peptide Sermorelin could be a potential treatment for a type of brain tumor called glioma. The scientists tested Sermorelin on cancer cells in a lab dish and found that it could stop the cancer cells from growing. The study suggests that Sermorelin might work by interfering with the cancer cells' ability to divide and multiply. It also seems to boost the immune system's ability to fight the cancer. This is an early-stage study, but it suggests that Sermorelin could be a promising new drug for patients with recurrent glioma.

 

Study 2: Advances in the detection of growth hormone releasing hormone synthetic analogs

Authors: Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V.

Source: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3183



Scientific Findings

This study investigates the in vitro metabolism of four growth hormone-releasing hormone (GHRH) synthetic analogs, including sermorelin, in fortified urine for anti-doping purposes. The researchers identified nineteen major in vitro metabolites of these GHRH analogs. For sermorelin, several degradation products were identified, which will aid in the development of more effective detection methods for its misuse in sports.



Plain English Interpretation

Scientists in this study were looking for a way to detect if athletes are illegally using substances like Sermorelin to enhance their performance. They developed a method to find these substances in urine. In the lab, they mixed Sermorelin with urine and observed how it breaks down. They identified several smaller pieces, or 'metabolites'. Knowing what these metabolites look like is crucial for creating a reliable drug test, because the test can then look for these specific markers.

 

Study 3: Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS

Authors: Knoop A, Thomas A, Fichant E, Delahaut P, Schänzer W, Thevis M.

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC4830873/



Scientific Findings

This study aimed to develop a method for detecting various growth hormone-releasing hormones (GHRHs), including Sermorelin, in human plasma for anti-doping purposes. In an in-vitro experiment, Sermorelin was incubated in human plasma. The researchers observed that Sermorelin was completely degraded after 4 hours. They identified a metabolite, GRF(3-29), which results from the cleavage of the N-terminal Tyr-Ala-residue by the enzyme dipeptidyl peptidase-IV (DPP-IV). This finding is important for developing effective anti-doping tests, as it's often the metabolites of a substance, rather than the substance itself, that are detected in biological samples.



Plain English Interpretation

Scientists in this study were looking for a way to detect if athletes are illegally using substances like Sermorelin to enhance their performance. They developed a method to find these substances in blood. In the lab, they mixed Sermorelin with human blood plasma and observed how it breaks down. They found that Sermorelin is broken down into a smaller piece, a 'metabolite'. Knowing what this metabolite looks like is crucial for creating a reliable drug test, because the test can then look for this specific marker.

Related products

Continue exploring the catalog